Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson's disease model.

Chunni ZhuTina BilousovaSamantha FochtMichael JunChris Jean EliasMikhail MelnikSujyoti ChandraJesus CampagnaWhitaker CohnAsa HatamiPatricia SpilmanKaren Hoppens GylysVarghese John

Published in: Molecular brain (2021)

In the acute study, pre-treatment with DDL-112 reduced EV/exosome biogenesis and in the chronic study, treatment with DDL-112 was associated with a reduction in αSyn aggregates in the substantia nigra and improvement in motor function. Inhibition of nSMase2 thus offers a new approach to therapeutic development for neurodegenerative diseases with the potential to reduce the spread of disease-specific proteopathic proteins.

Keyphrases

drug induced
intensive care unit
replacement therapy
combination therapy
resting state
acute respiratory distress syndrome